<?xml version="1.0" encoding="UTF-8"?>
<p id="Par4">Systemic corticosteroids (CS) are known to potently dampen immune inflammation. Like in inflammatory rheumatic diseases, CS might serve as a “bridge” to specific efficient antiviral therapy for COVID-19. Despite the common fears of the virus replication, provisional recommendations for managing excessive inflammatory response in COVID-19 include intravenous CS [
 <xref ref-type="bibr" rid="CR5">5</xref>]. The World Health Organization (WHO), however, recommends to avoid routine administration of systemic CS for the treatment of viral pneumonia outside clinical trials [
 <xref ref-type="bibr" rid="CR6">6</xref>].
</p>
